Stories from people navigating immunotherapy — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Health Policy
The FDA authorized dostarlimab for eligible adults with stage II or III locally advanced rectal cancer, based on a 154-patient efficacy assessment. Confirmation of long-term clinical benefit is still required.
Rayan Salih · November 2, 2026 · 7 min
Oncology
ASTRUM-006 found an event-free survival benefit from adding serplulimab to perioperative SOX in PD-L1-positive, resectable gastric or gastroesophageal junction adenocarcinoma.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.